Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of macrolide antibiotics in blocking influenza virus infection

An influenza virus infection, macrolide technology, applied in the direction of antiviral agents, medical preparations containing active ingredients, amine active ingredients, etc.

Inactive Publication Date: 2019-06-04
SUZHOU INST OF SYST MEDICINE
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, in the existing prior art about macrolide antibiotics, there is no report that macrolide antibiotics are used as active ingredients to directly inhibit influenza virus infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of macrolide antibiotics in blocking influenza virus infection
  • Application of macrolide antibiotics in blocking influenza virus infection
  • Application of macrolide antibiotics in blocking influenza virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] Example 1 : Macrolide antibiotics have the ability to resist the infection of influenza A virus A / PuertoRico / 8 / 34(PR8)-Luc

[0061] A549 cells (human lung cancer epithelial cells) are an ideal cell line for studying influenza virus. The inventors used the IAV-Luc influenza virus model with the luciferase reporter gene constructed by the research group of Chen Ling, Chinese Academy of Sciences using a reverse genetic system ( Using influenza virus PR8 as the backbone, a humanized luciferase gene is added to the C-terminus of the NA coding gene) against a number of marketed small molecule antibiotics (including the 14-membered ring macrolide antibiotic erythromycin, erythromycin 15-membered ring macrolide antibiotic azithromycin and 16-membered ring macrolide antibiotic acetylspiramycin, midecamycin) were evaluated for anti-influenza virus infection ability. The inventor first seeded A549 cells in a 96-well plate at 10,000 cells per well, incubated the drug 16 hours lat...

Embodiment 2

[0063] Example 2 : Comparison of Azithromycin and Oseltamivir Anti-Influenza Virus Infection

[0064] Since azithromycin often acts as an adjuvant when oseltamivir treats influenza virus in the prior art, the ability of azithromycin and oseltamivir to resist influenza virus infection was compared separately. Using the same experimental method steps as in Example 1, the anti-infection capabilities of azithromycin and oseltamivir were compared.

[0065] Such as image 3 As shown, after data analysis, it was found that azithromycin had stronger anti-influenza virus infection ability than oseltamivir at the same concentration (10 μM).

Embodiment 3

[0066] Example 3 : Azithromycin can prevent Barb / C mice against A / WSN33 / H1N1

[0067] Twenty-four female Barb / C mice aged 6-8 weeks were randomly divided into 4 groups (A, B, C, D) with 5 mice in each group. Ear piercings of all animals were marked, and then treated with designated preparations: group A was a blank control group; group B was a challenged PBS group, group C was a challenged ribavirin group, and group D was a challenged azithromycin group. Two days before the challenge, 50mg / kg of ribavirin and 50mg / kg of azithromycin were administered orally, and on the third day, 40 LD 50 (10 3 PFU / ml) dose of influenza virus intranasally infected mice, each 50 μl, the blank group was replaced by PBS, administered continuously for 5 days after the challenge, the administration method was the same as above, after fasting for 12 hours, weighed, The lungs were aseptically weighed after eyeball bleeding, and the lung index was calculated to evaluate the protective effect of azit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of macrolide antibiotics in blocking influenza virus infection, specifically, the invention discloses the application of macrolide antibiotics including azithromycin, erythromycin, roxithromycin, medimycin or acetylspiramycin or pharmaceutically acceptable salt thereof for blocking influenza virus infection, and the application of the macrolide antibiotics in preparation of a medicinefor treating or preventing influenza virus infection. The experiments confirm that the aforementioned macrolide antibiotics have the ability to resist influenza virus infection and are capable of performing prophylactic treatment of influenza virus infection. At the same time, the invention also validates the action mechanism of azithromycin for treatment of influenza. Therefore, the aforementioned macrolide antibiotics or the pharmaceutically acceptable salt thereof and a composition comprising the aforementioned macrolide antibiotics can be prepared as the medicinefor treating or preventing the influenza virus infection.

Description

technical field [0001] The present disclosure relates to a class of antibiotics and the application of compositions containing the aforementioned antibiotics in the preparation of drugs for the prevention and treatment of diseases, specifically, macrolide antibiotics or pharmaceutically acceptable salts thereof and compositions containing the aforementioned antibiotics or their Application of pharmaceutically acceptable salt composition in preparation of medicament for blocking influenza virus infection. Background technique [0002] Influenza virus is a pathogen that seriously threatens human health and life safety. It can be divided into three types: A (A), B (B), and C (C). Among them, the antigenicity of type A influenza virus is easily mutated and has caused pandemics many times. . For example, in 2009, the swine-origin H1N1 influenza virus infected humans and spread widely among the population, constituting the first influenza pandemic in the 21st century. The number ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7052A61K31/7048A61P31/16
CPCA61K31/13A61K31/215A61K31/351A61K31/7048A61K31/7052A61P31/16
Inventor 秦晓峰左向阳杜晓红吴飞
Owner SUZHOU INST OF SYST MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com